Floatz logo

Datopotamab Deruxtecan

Residual Disease

UNC Lineberger Comprehensive Cancer Centerantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Residual Disease cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
University of Chicago
Phase 2B
cc-5013
University of Chicago
Phase 2B
mln9708
University of Chicago
Phase 2B
Wokvac Vaccine
H. Lee Moffitt Cancer Center and Research Institute
Phase 2CCC
Epirubicin
Dartmouth-Hitchcock Medical Center
Phase 1/2CC

View all 13 →

Same molecule, other indications

Datopotamab Deruxtecan is also rated in:

stomatitisDormant
BB
Indicative ·
65 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
63 / 100
View asset →
biliary tract cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →